Related Experiment Video
Updated: May 28, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody
Thomas B Voigt1,2, Noor Ghosh1, Brandon C Rosen1,3
1Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Abstract:
Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic and often lethal zoonotic viruses with broad species tropism and no approved human vaccines. The emergence of genetically divergent HNVs-including Ghana virus (GhV), Langya virus (LayV), and Mojiang virus (MojV)-emphasizes the need for broadly protective countermeasures. Here, we evaluated the antibody (Ab) responses to sequential mRNA vaccines encoding the membrane-bound attachment glycoprotein (gG) from NiV, GhV, and/or LayV in a pilot study with Indian rhesus macaques. Serum binding Ab responses were quantified by ELISA against five soluble gG antigens (NiV, HeV, GhV, LayV, MojV). Functional activity was assessed by neutralization assays using NiV, HeV, and GhV pseudoviruses, and by receptor-blocking ELISA. Sequential vaccination induced high-titer IgG binding against all five HNV gGs with increasing breadth after each dose. Pan-genus regimens elicited moderate neutralizing Ab titers against NiV, HeV, and GhV, whereas the NiV-only regimen elicited potent but narrow neutralization against NiV and HeV. Conversely, the GhV-LayV-GhV regimen elicited strong binding to GhV, LayV, and MojV gG and robust neutralization of GhV pseudovirus, but limited cross-reactivity to NiV and HeV. In this pilot study, we demonstrated that mRNA vaccination can elicit broadly reactive binding and neutralizing Ab responses across phylogenetically distant HNVs. Additionally, we show GhV pseudovirus neutralization for the first time. Collectively, these data provide a foundation for the development of next-generation pan-genus HNV vaccines capable of mitigating future HNV outbreaks.
Insights
New mRNA vaccines show promise for broad protection against deadly Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV). Sequential vaccination in macaques generated robust antibody responses, paving the way for effective countermeasures against future HNV outbreaks.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Henipaviruses (HNVs), such as Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic zoonotic viruses lacking approved human vaccines.
- Emerging divergent HNVs like Ghana virus (GhV), Langya virus (LayV), and Mojiang virus (MojV) necessitate broadly protective vaccine strategies.
Purpose of the Study:
- To evaluate antibody responses to sequential mRNA vaccines encoding the attachment glycoprotein (gG) of NiV, GhV, and/or LayV in Indian rhesus macaques.
- To assess the breadth and functionality of antibody responses against diverse HNVs.
Main Methods:
- Pilot study involving sequential mRNA vaccination in rhesus macaques.
- Quantification of serum binding antibody responses via ELISA against five HNV gG antigens.
- Assessment of functional activity through neutralization assays with pseudoviruses and receptor-blocking ELISA.
Main Results:
- Sequential vaccination induced high-titer, broad IgG binding responses against all five tested HNV gGs.
- Pan-genus vaccine regimens elicited moderate neutralizing antibody titers against NiV, HeV, and GhV.
- Specific regimens demonstrated potent but narrow neutralization (NiV-only) or robust GhV neutralization with limited cross-reactivity (GhV-LayV-GhV).
Conclusions:
- mRNA vaccination can elicit broadly reactive binding and neutralizing antibodies across divergent HNVs.
- This study provides the first evidence of GhV pseudovirus neutralization.
- Findings support the development of next-generation pan-genus HNV vaccines to mitigate future outbreaks.
Related Concept Videos
Respiratory Syncytial Virus Disease
Cross-reactivity

